Agilon Health Shares Surge 18% After Q4 Revenue Beat and EBITDA Outlook
Agilon Health reported Q4 2025 revenue of $1.57 billion, up 3.1% year-over-year, beating consensus estimates and offering EBITDA guidance above forecasts. The company logged a GAAP loss of $0.46 per share and set Q1 2026 revenue guidance at $1.37 billion, below analyst projections.
1. Q4 2025 Performance
Agilon Health posted Q4 2025 revenue of $1.57 billion, up 3.1% year-over-year, exceeding consensus forecasts. The company reported a GAAP loss of $0.46 per share, missing analyst estimates due to higher operating costs and integration expenses.
2. EBITDA Outlook
Management provided EBITDA guidance for Q1 2026 that surpassed analyst projections, citing margin improvement initiatives and cost‐optimization measures expected to drive profitability in the coming quarter.
3. Q1 2026 Revenue Guidance
Agilon issued revenue guidance of $1.37 billion for Q1 2026, falling short of market expectations as conservative enrollment growth assumptions weighed on near-term sales outlook.
4. Market Reaction
Shares jumped 18% in afternoon trading as investors focused on the revenue beat and positive EBITDA outlook, offsetting concerns over the earnings miss and softer first-quarter revenue forecast.